

1 **Curved intertrochanteric varus osteotomy versus total hip arthroplasty for**
2 **osteonecrosis of the femoral head in patients under 50 years old**

3

4 ¹ **List of abbreviations**

5

¹ CVO, Curved intertrochanteric varus osteotomy; HHS, Harris hip score; JHEQ, Japanese Orthopaedic Association Hip-Disease Evaluation Questionnaire; MCS, Mental Component Summary; OHS, Oxford hip score; ONFH, Osteonecrosis of the femoral head; PCS, Physical Component Summary; PRO, Patient-reported outcomes; RCS, Role/Social Component Summary; ROM, Range of motion; THA, Total hip arthroplasty

6

7 **Abstract**

8 **Background:** Given recent advances in total hip arthroplasty (THA), curved
9 intertrochanteric varus osteotomy (CVO) is not indicated as a treatment for
10 osteonecrosis of the femoral head (ONFH), unless maintaining long-term hip function
11 and patient satisfaction. We aimed to compare the clinical outcomes of CVO with those
12 of THA for treatment of ONFH in young adults <50 years old.

13 **Methods:** This comparative study included 105 ONFH patients: 59 patients, 67 hips
14 who underwent CVO and 46 patients, 56 hips who underwent THA. Assessment tools
15 included the Harris hip score (HHS), patient-reported outcomes of the Short Form 36
16 (SF-36), Oxford hip score (OHS), Japanese Orthopaedic Association Hip-Disease
17 Evaluation Questionnaire (JHEQ), University of California Los Angeles (UCLA) score,
18 together with complication and survival rates.

19 **Results:** Preoperative HHS was significantly higher in the CVO group than the THA
20 group. ($p < 0.01$) No between-group differences were noted in HHS or the following
21 patient-reported outcomes at last follow-up: all domains of JHEQ scores, OHS, and
22 SF-36. UCLA scores and complication rates were comparable: 3% for the CVO and 7%
23 for the THA group. The 10-year survival rate with surgery for any reason as the
24 endpoint was comparable, at 91.8% for the CVO and 97.7% for the THA group.

25 **Conclusion:** Functional outcomes, survival rate, and sporting activities for patients <50
26 years old undergoing CVO or THA for ONFH were comparable at a mean follow-up of
27 10 years. Strict indications for CVO can help maintain hip function and patient
28 satisfaction equivalent to that for THA, in the long term.

29

30 **Keywords:** osteonecrosis of the femoral head, curved intertrochanteric varus osteotomy,

31 total hip arthroplasty, comparative study

32

33

34 **Introduction**

35 Osteonecrosis of the femoral head (ONFH) is defined as collapse of the femoral head,
36 with secondary osteoarthritis leading to severe hip pain and restriction in daily activities
37 [1, 2]. ONFH often occurs in young adults and requires early intervention, which makes
38 treatment choice difficult [3]. Although total hip arthroplasty (THA) is the most widely
39 used surgical procedure for the treatment of ONFH [4], high rates of revision surgery
40 and of complications have been reported for this operation [5]. Therefore, joint
41 preservation surgery might be preferred for ONFH patients aged <50 years.

42 Curved intertrochanteric varus osteotomy (CVO) was developed as a treatment for
43 osteoarthritis secondary to acetabular dysplasia, and several studies have reported
44 favorable clinical outcomes for its use in ONFH [6-8]. CVO was indicated in patients
45 who could obtain coverage of more than one-third of the weight-bearing area with an
46 intact articular surface, based on preoperative anteroposterior radiographs of the hip in
47 maximum abduction [6, 8, 9]. CVO is a relatively simple surgical procedure; it prevents
48 weakening of the gluteus medius and minimus muscles as well as leg-length
49 discrepancy, which are disadvantages of conventional varus wedge osteotomy [7].

50 The choice of treatment for ONFH in young adults is controversial. While there have
51 been recent advances in THA, leading to good postoperative outcomes, it is not clear
52 whether this is the case for adults aged <50 years. It is important to prioritize procedures,
53 including joint preservation surgery, that allow long-term maintenance of hip function
54 and patient satisfaction. Thus, this study aimed to compare the clinical outcomes of
55 CVO and THA for ONFH patients aged <50 years.

56

57 **Patients and Methods**

58 **Design**

59 This study was based on a retrospective chart review and was approved by our
60 Institutional Review Board. All patients provided their written informed consent to
61 participate. The study included 216 patients who consecutively underwent CVO (96
62 patients) or THA (110 patients) for non-traumatic ONFH between January 1999 and
63 May 2014. Seventy-two patients aged >50 years were excluded. Of the remaining 143
64 patients, 31 who underwent different operations for each hip and eight who could not be
65 observed for more than five years were also excluded. Therefore, the CVO group finally
66 consisted of 59 patients (36 men and 23 women; 65 hips; mean age, 37.7 (range, 18–49)
67 years), while the THA group comprised 46 patients (28 men and 18 women; 56 hips;
68 mean age, 39.2 (range, 17-49) years) (Figure 1). The patients in each group were
69 followed for a mean duration of 11.5 (range, 5-18) years and 10.7 (range, 5-18) years,
70 respectively. Six patients (10%) in the CVO group and 10 patients (22%) in the THA
71 group had bilateral CVO or THA. The stage and type of ONFH were classified as
72 described by the Japanese Investigation Committee of the Ministry of Health, Labour
73 and Welfare [10]. In the CVO group, 19 hips were stage 2 (sclerosis without femoral
74 head collapse), 29 were stage 3A (femoral head collapse of <3 mm), and 17 were stage
75 3B (femoral head collapse of >3 mm). In the THA group, stage 3B comprised 15 hips
76 and stage 4, 41 hips. Seven hips were type B, 44 type C1, and 14 type C2 in the CVO
77 group; while five hips were type B, 19 type C1 and 32 type C2 in the THA group. No
78 significant differences in sex, age, body mass index or follow-up duration, except for
79 stage and type classification, were found between the groups (Table 1).

80

81 **Surgical indication and technique**

82 In general, joint preservation surgery is indicated for patients under 50 years old. CVO
83 was performed in patients who could obtain coverage of more than one-third of the
84 weight-bearing area with an intact articular surface, based on preoperative
85 anteroposterior radiographs of the hip in maximum abduction. If there was no other
86 indication for CVO and there was an intact articulating circumference exceeding
87 one-third of the entire circumference in Lauenstein's view, we selected transtrochanteric
88 rotational osteotomy [11]. THA was selected for patients in whom there was no
89 indication for, or who did not wish to undergo, joint preservation surgery, and also for
90 cases with stage 4 ONFH.

91 The operative technique of CVO has been described previously [6, 9]. Briefly, an
92 osteotomy guide is attached to a line from the top of the greater trochanter to a point 2–
93 3 mm above the middle of the lesser trochanter. After performing the curved osteotomy,
94 the femoral head is rotated into a varus position by displacing the femoral neck in the
95 cranial direction. The femoral head is then stabilized using two or three screws, or
96 compression hip screws. Patients are allowed to walk with 10-kg partial weight bearing,
97 using two crutches, from the first day after surgery. Full-weight bearing is allowed at
98 10–12 weeks post-surgery.

99 THA was performed in all patients using a standard posterior approach, with the
100 patient in the lateral decubitus position. The type of implant in the THA group was the
101 Super Secur-Fit stem in 36 hips, the Secur-Fit stem in 14, the Omnifit C stem in six, the
102 Trident HA cup in 40, the TriAD HA cup in 11 and the Secur-Fit AD cup in five (all
103 implants were Stryker Orthopedics, Mahwah, NJ). Generally, walking practice with
104 full-weight bearing was allowed. All CVO and THA procedures were performed or
105 supervised by a single senior surgeon.

106

107 **Measurements**

108 We evaluated hip function using the Harris Hip Score (HHS) and range of motion
109 (ROM) preoperatively and at the final follow-up. Patient-reported outcomes (PRO)
110 were evaluated using the Japanese version of the Short Form-36 (SF-36) [12, 13].
111 Oxford Hip Score (OHS) [14], and Japanese Orthopaedic Association Hip-Disease
112 Evaluation Questionnaire (JHEQ) [15] for health status. Scores for the Physical
113 Component Summary (PCS), Mental Component Summary (MCS), and Role/Social
114 Component Summary (RCS) domains of the SF-36 were evaluated. The OHS is scored
115 in a range from 0 (worst) to 48 (best), as reported by Murray et al. [16] The JHEQ
116 consists of three components: pain, movement, and mental health. Each component is
117 scored in a range from 0 (worst) to 28 (best). The total score therefore ranges between 0
118 (worst) and 84 (best). In addition, assessment by the University of California, Los
119 Angeles (UCLA) score was performed to assess patient sports activity [17]. When the
120 assessment questionnaires were sent to the patients after the last follow-up, the response
121 rate was 86% (51/59) for the CVO group and 91% (42/46) for the THA group. The
122 overall response rate was 89% (93/105).

123

124 **Statistical analysis**

125 Statistical analysis was performed with SPSS version 21 (IBM Corp., Armonk, NY,
126 USA). The analyses consisted of Student's t-test for continuous variables, the
127 Mann-Whitney U test for non-continuous variables, and Fisher's exact test for
128 categorical variables. Survival rates were examined using the Kaplan–Meier method
129 with any reason due to revision surgery as the endpoints. The groups were compared

130 using a log-rank analysis. P-values less than 0.05 were considered statistically
131 significant.

132

133 **Results**

134 Our findings indicated a significant difference in preoperative HHS, when comparing
135 the CVO (70.2 ± 9.6) and THA groups (59.6 ± 5.8) ($p < 0.01$). However, the HHS at
136 final follow-up showed no such difference (CVO 88.2 ± 9.1 and THA 91.6 ± 7.4).

137 However, pain score of HHS tended to be poorer in the CVO group than in the THA
138 group. With regard to the range of motion (ROM), preoperatively all ROMs expect for
139 adduction, were significantly greater in the CVO than the THA group (all $p < 0.01$).

140 Postoperatively, the ROM in abduction was significantly greater in the THA than the
141 CVO group ($p < 0.01$; Table 2). No between-group differences were noted at the last
142 follow-up, with regard to any domain of the SF-36, OHS, and JHEQ scores. Pain score
143 of JHEQ tended to be poorer in the CVO group than in the THA group. In addition, the
144 UCLA score at the last follow-up showed no significant differences between the CVO
145 (4.9 ± 1.8) and THA groups (5.1 ± 1.9) (Table 3).

146 No between-group difference in the rate of complication was found. There were two
147 cases of peri-implant fracture in the CVO group, and one case of infection and
148 periprosthetic fracture plus two cases of dislocation in the THA group. Conversion
149 operations to THA due to secondary osteoarthritis were performed in five patients in the
150 CVO group, and revision surgery was required in two cases in the THA group (one case
151 of periprosthetic fracture and one case of aseptic loosening). The 10-year survival rate
152 with reoperation as an endpoint (Figure 2) was 91.8% for the CVO group and 97.7% for
153 the THA group at 10 years ($p = 0.532$).

154

155 **Discussion**

156 Treatment selection for ONFH in patients <50 years old, especially in younger adults,
157 is controversial. Previous reports demonstrated poor clinical outcomes of THA for
158 ONFH because ONFH patients were relatively young, and highly active [4]. With the
159 recent progress in THA, favorable long-term results in ONFH patients <50 years old
160 have been reported [18, 19]. However, recent reports showed that the rate of revision
161 surgery is higher in ONFH than in osteoarthritis [20]. In addition, the Norwegian
162 registry demonstrated poor clinical results of THA for younger adults, and the
163 possibility of multiple future revision operations should be considered [21]. The use of
164 osteotomy for ONFH has been declining in recent years [22] because it does not always
165 provide good long-term results [23]. However, favorable clinical outcomes for CVO,
166 mainly in Japan, have been reported [6-8]. In this study, the joint survival rate in the
167 CVO group was 91%, with reoperation as the endpoint, and we believe that this
168 procedure may have played a significant role in joint preservation (Figure 3).

169 Previous reports demonstrated that poor clinical outcomes when postoperative
170 coverage is less than 33.4-40% [6-8]. Therefore, in general, CVO is indicated in patients
171 who could obtain coverage of more than one-third of the weight-bearing area with an
172 intact articular surface, based on preoperative anteroposterior radiographs of the hip in
173 maximum abduction. In our previous study, the 10-year survival rate of 47% with Type
174 C2 ONFH as the endpoint of radiographic failure was poor [7], so only Type B and C1
175 ONFH, who could obtain coverage of more than one-third of the weight-bearing area
176 with an intact articular surface, are currently indicated for this method. As other risk
177 factors, Okura et al. reported poor treatment outcomes for dysplastic hips with a CE

178 angle of less than 25 degree [7]. Kubo et al. reported that the presence of anterior
179 necrotic lesion was a risk factor for osteoarthritis changes [24]. Careful consideration
180 should be given to the indication of CVO to prevent future progression of osteoarthritis.

181 There have been few reports on PRO of osteotomy for ONFH. Seki et al. reported no
182 significant difference in SF-36 results between THA and osteotomy for ONFH in a
183 cross-sectional study [25]. Kubo et al. evaluated trochanteric rotational osteotomy and
184 THA and reported no significant difference in postoperative PRO at 1 year [26]. In our
185 study, there was almost no difference in patient-reported hip function, nor in satisfaction
186 between the two groups. We believe that favorable hip function can be maintained in the
187 long term if the CVO indication is strictly selected. However, the CVO group showed
188 slightly poor outcomes with regard to pain score of JHEQ as well as pain score of HHS,
189 which we considered possibly due to secondary osteoarthritis; although the difference
190 was not statistically significant.

191 Previous studies demonstrated that 64%-74% of patients who underwent THA
192 participated in sports [27, 28] and the postoperative UCLA score after THA was 6.6-6.9
193 [29, 30]. In the present study, UCLA score after THA (5.1) was poor compared to
194 reported UCLA scores in previous studies. In contrast, almost no study has reported on
195 the sporting activities of ONFH patients post-osteotomy. According to our results, the
196 UCLA score of the CVO group was almost equivalent to the THA group. However,
197 outcomes related to sporting activities were not good in either group. We believe that
198 the scores may have been affected by the characteristics of ONFH patients with
199 alcoholic backgrounds, and by primary pathology caused by steroid use. It is also
200 possible that sporting activities were voluntarily restricted due to concerns regarding the
201 risk of reoperation and complications. Therefore, patient guidance was considered

202 necessary to obtain greater patient satisfaction after hip surgery for ONFH.

203 There are several limitations to this study. First, the number of patients in this study
204 were small and a greater number of patients would have been preferable to increase the
205 statistical power. However, ONFH is a rare disease, and its annual incidence in Japan
206 has been reported to be an average of 2.51 cases per 100000 persons [31], it is difficult
207 to collect many patients. Second, there may be a significant difference in preoperative
208 HHS because of differences in disease stage and ONFH classification between the
209 groups. However, previous reports demonstrated the postoperative outcomes of THA
210 due to differences in stage, were similar except for ROM [32]; therefore, we believe the
211 final outcome was not significantly affected. Furthermore, preoperative PRO could not
212 be evaluated in this study; a previous study reported that PRO was significantly poorer
213 in the more severe stages [3] but preoperative PRO was poorer in the THA than the
214 CVO group.

215 Recent advances in THA have resulted in many favorable long-term outcomes for
216 ONFH [18, 19, 33], while registries have poor THA outcomes in younger adults, and the
217 risk of multiple future revisions must be considered [21]. Therefore, we consider joint
218 preservation surgery to be the first choice for ONFH in adults less than 50 years old.
219 However, revision THA after CVO is technically difficult due to anatomical deformity
220 [34], and recovery of muscle strength and ROM is inferior to that after primary THA,
221 due to contracture following reoperation [35]. Consequently, operative indications
222 should be strictly followed when performing CVO, and if osteoarthritis develops after
223 CVO, careful attention paid to the timing of conversion to THA.

224 In conclusion, the clinical results of CVO and THA for ONFH in patients less than 50
225 years old were almost equivalent. Strict operative indications for CVO can ensure

226 maintenance of hip function and patient satisfaction equivalent to THA in the long term.

227

228

229 **References**

- 230 [1] **Hauzeur J-P, Malaise M, Maertelaer VD.** A prospective cohort study of the
231 clinical presentation of non-traumatic osteonecrosis of the femoral head: spine and
232 knee symptoms as clinical presentation of hip osteonecrosis. *Int Orthop.*
233 2016;40(7):1347-1351.
- 234 [2] **Johansson HR, Zywiol MG, Marker DR, Jones LC, Mcgrath MS, Mont MA.**
235 Osteonecrosis is not a predictor of poor outcomes in primary total hip arthroplasty:
236 a systematic literature review. *Int Orthop.* 2011;35(4):465-473.
- 237 [3] **Osawa Y, Seki T, Takegami Y, Kasai T, Higuchi Y, Ishiguro N.** Do femoral head
238 collapse and the contralateral condition affect patient-reported quality of life and
239 referral pain in patients with osteonecrosis of the femoral head? *Int Orthop.*
240 2018;42(7):1463-1468.
- 241 [4] **Issa K, Pivec R, Kapadia BH, Banerjee S, Mont MA.** Osteonecrosis of the
242 femoral head. *Bone Joint J.* 2013;95-B(11_Supple_A):46-50.
- 243 [5] **Radl R, Hungerford M, Materna W, Rehak P, Windhager R.** Higher failure rate
244 and stem migration of an uncemented femoral component in patients with femoral
245 head osteonecrosis than in patients with osteoarthritis. *Acta Orthop.*
246 2005;76(1):49-55.
- 247 [6] **Hamanishi M, Yasunaga Y, Yamasaki T, Mori R, Shoji T, Ochi M.** The clinical
248 and radiographic results of intertrochanteric curved varus osteotomy for idiopathic
249 osteonecrosis of the femoral head. *Arch Orthop Trauma Surg.* 2014;134(3):305-310.
- 250 [7] **Okura T, Hasegawa Y, Morita D, Osawa Y, Ishiguro N.** What factors predict the
251 failure of curved intertrochanteric varus osteotomy for the osteonecrosis of the

- 252 femoral head? *Arch Orthop Trauma Surg.* 2016;136(12):1647-1655.
- 253 [8] **Zhao G, Yamamoto T, Ikemura S, et al.** Radiological outcome analysis of
254 transtrochanteric curved varus osteotomy for osteonecrosis of the femoral head at a
255 mean follow-up of 12.4 years. *J Bone Joint Surg Br.* 2010;92-B(6):781-786.
- 256 [9] **Sakano S, Hasegawa Y, Torii Y, Kawasaki M, Ishiguro N.** Curved
257 intertrochanteric varus osteotomy for osteonecrosis of the femoral head. *J Bone*
258 *Joint Surg Br.* 2004;86-B(3):359-365.
- 259 [10] **Sugano N, Kubo T, Takaoka K, et al.** Diagnostic criteria for non-traumatic
260 osteonecrosis of the femoral head. *J Bone Joint Surg Br.* 1999;81-B(4):590-595.
- 261 [11] **Sugioka Y.** Transtrochanteric anterior rotational osteotomy of the femoral head in
262 the treatment of osteonecrosis affecting the hip: a new osteotomy operation. *Clin*
263 *Orthop Relat Res* 1978;(130):191.
- 264 [12] **Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K.** Translation, Adaptation,
265 and Validation of the SF-36 Health Survey for Use in Japan. *J Clin Epidemiol.*
266 1998;51(11):1037-1044.
- 267 [13] **Ware JE, Sherbourne CD.** The MOS 36-Item Short-Form Health Survey (SF-36).
268 *Medical Care.* 1992;30(6):473-483.
- 269 [14] **Dawson J, Fitzpatrick R, Murray D, Carr A.** Comparison of measures to assess
270 outcomes in total hip replacement surgery. *Quality and Safety in Health Care.*
271 1996;5(2):81-88.
- 272 [15] **Matsumoto T, Kaneuji A, Hiejima Y, et al.** Japanese Orthopaedic Association
273 Hip Disease Evaluation Questionnaire (JHEQ): a patient-based evaluation tool for
274 hip-joint disease. The Subcommittee on Hip Disease Evaluation of the Clinical
275 Outcome Committee of the Japanese Orthopaedic Association. *J Orthop Sci.*
276 2012;17(1):25-38.

- 277 [16] **Murray DW, Fitzpatrick R, Rogers K, et al.** The use of the Oxford hip and knee
278 scores. *J Bone Joint Surg Br.* 2007;89-B(8):1010-1014.
- 279 [17] **Amstutz HC, Thomas BJ, Jinnah R, Kim W, Grogan T, Yale C.** Treatment of
280 primary osteoarthritis of the hip. A comparison of total joint and surface
281 replacement arthroplasty. *The Journal of Bone & Joint Surgery.*
282 1984;66(2):228-241.
- 283 [18] **Kim Y-H, Park J-W, Kim J-S.** Alumina Delta-on-Alumina Delta Bearing in
284 Cementless Total Hip Arthroplasty in Patients Aged <50 Years. *J Arthroplasty.*
285 2016;31(10):2209-2214.
- 286 [19] **Mclaughlin JR, Lee KR.** Total Hip Arthroplasty with an Uncemented Tapered
287 Femoral Component in Patients Younger Than 50 Years of Age: A Minimum
288 20-Year Follow-Up Study. *J Arthroplasty.* 2016;31(6):1275-1278.
- 289 [20] **Ancelin D, Reina N, Cavaignac E, Delclaux S, Chiron P.** Total hip arthroplasty
290 survival in femoral head avascular necrosis versus primary hip osteoarthritis:
291 Case-control study with a mean 10-year follow-up after anatomical cementless
292 metal-on-metal 28-mm replacement. *Orthop Traumatol Surg*
293 *Res.* 2016;102(8):1029-1034.
- 294 [21] **Tsukanaka M, Halvorsen V, Nordsletten L, et al.** Implant survival and
295 radiographic outcome of total hip replacement in patients less than 20 years old.
296 *Acta Orthop.* 2016;87(5):479-484.
- 297 [22] **Johnson AJ, Mont MA, Tsao AK, Jones LC.** Treatment of Femoral Head
298 Osteonecrosis in the United States: 16-year Analysis of the Nationwide Inpatient
299 Sample. *Clin Orthop Relat Res* ®. 2014;472(2):617-623.
- 300 [23] **Morita D, Hasegawa Y, Okura T, Osawa Y, Ishiguro N.** Long-term outcomes of
301 transtrochanteric rotational osteotomy for non-traumatic osteonecrosis of the
302 femoral head. *Bone Joint J.* 2017;99-B(2):175-183.
- 303 [24] **Kubo Y, Motomura G, Ikemura S, et al.** Effects of anterior boundary of the
304 necrotic lesion on the progressive collapse after varus osteotomy for osteonecrosis

305 of the femoral head. *J Orthop Sci.* 2019 Mar 7. pii: S0949-2658(19)30063-6.

306 [25] **Seki T, Hasegawa Y, Masui T, et al.** Quality of life following femoral osteotomy
307 and total hip arthroplasty for nontraumatic osteonecrosis of the femoral head. *J*
308 *Orthop Sci.* 2008;13(2):116-121.

309 [26] **Kubo Y, Yamamoto T, Motomura G, Karasuyama K, Sonoda K, Iwamoto Y.**
310 Patient-reported outcomes of femoral osteotomy and total hip arthroplasty for
311 osteonecrosis of the femoral head: a prospective case series study. *Springer Plus.*
312 2016;5(1).

313 [27] **Ollivier M, Frey S, Parratte S, Flecher X, Argenson JN.** Pre-operative function,
314 motivation and duration of symptoms predict sporting participation after total hip
315 replacement. *Bone Joint J.* 2014;96-B(8):1041-1046.

316 [28] **Wylde V, Blom A, Dieppe P, Hewlett S, Learmonth I.** Return to sport after joint
317 replacement. *J Bone Joint Surg Br.* 2008;90-B(7):920-923.

318 [29] **Gray BL, Stambough JB, Baca GR, Schoenecker PL, Clohisy JC.** Comparison
319 of contemporary periacetabular osteotomy for hip dysplasia with total hip
320 arthroplasty for hip osteoarthritis. *Bone Joint J.* 2015;97-B(10):1322-1327.

321 [30] **Kalore NV, Cheppalli SP, Daner WE, Jiranek WA.** Acetabular Dysplasia in
322 Middle-Aged Patients: Periacetabular Osteotomy or Total Hip Arthroplasty? *J*
323 *Arthroplasty.* 2016;31(9):1894-1898.

324 [31] **Takahashi S, Fukushima W, Yamamoto T, et al ; Japanese Sentinel Monitoring**
325 **Study Group for Idiopathic Osteonecrosis of the Femoral Head.** Temporal
326 Trends in Characteristics of Newly Diagnosed Nontraumatic Osteonecrosis of the
327 Femoral Head From 1997 to 2011: A Hospital-Based Sentinel Monitoring System
328 in Japan.

329 J Epidemiol. 2015;25(6):437-44.

330 [32] **Jo W-L, Lee Y-K, Ha Y-C, Kim T-Y, Koo K-H.** Delay of total hip arthroplasty to
331 advanced stage worsens post-operative hip motion in patients with femoral head
332 osteonecrosis. *Int Orthop.* 2018;42(7):1599-1603.

333 [33] **Osawa Y, Seki T, Takegami Y, Kusano T, Makida K, Ishiguro N.** Cementless
334 total hip arthroplasty for osteonecrosis and osteoarthritis produce similar results at
335 ten years follow-up when matched for age and gender. *Int Orthop.*
336 2018;42(7):1683-1688.

337 [34] **Takegami Y, Komatsu D, Seki T, Ishiguro N, Hasegawa Y.** Total hip arthroplasty
338 after failed curved intertrochanteric varus osteotomy for avascular necrosis of the
339 femoral head. *Journal of Medical Science.* 2016;78(1):89-97.

340 [35] **Osawa Y, Seki T, Morita D, Takegami Y, Okura T, Ishiguro N.** Total Hip
341 Arthroplasty After Transtrochanteric Rotational Osteotomy for Osteonecrosis of
342 the Femoral Head: A Mean 10-Year Follow-Up. *J Arthroplasty.*
343 2017;32(10):3088-3092.

344